Key result
Untreated atrial fibrillation patients had higher platelet activation markers than healthy controls, and treatment with warfarin or aspirin failed to significantly reduce platelet activation.
Why the study?
Platelet function may be abnormal in patients with AF and related to abnormal thrombogenesis, prompting investigation into platelet activation and the effects of antithrombotic therapy.
Does antithrombotic therapy (aspirin or warfarin) improve platelet activation and coagulation markers in patients with atrial fibrillation compared to no therapy?
Cross-Sectional (n=288)
Does antithrombotic therapy (aspirin or warfarin) improve platelet activation and coagulation markers in patients with atrial fibrillation compared to no therapy?
Atrial fibrillation is associated with increased platelet activation and thrombogenesis, but standard antithrombotic therapies (aspirin, warfarin) do not significantly reduce platelet activation, suggesting it may not be the primary driver of thromboembolism in AF.
Answers are grounded in this paper and cite their sources.
No aggregation abnormalities in AF despite marker shifts; leaves open platelet activation's role in thromboembolic risk.
BACKGROUND: Platelet function may be abnormal in patients with atrial fibrillation (AF) and could be related to abnormal thrombogenesis. The aim of this cross-sectional study was to investigate new aspects of platelet biology in AF, predominantly focusing on platelet activation and the effects of concomitant antiplatelet and anticoagulant therapy. PATIENTS AND METHODS: The study group of 238 patients were (i). 93 patients on no antithrombotic therapy, (ii). 60 patients taking 75-325 mg aspirin/day, and (iii). 85 patients on dose-adjusted warfarin (International Normalised Ratio [INR] range 2.0-3.0). Results were compared with those from 50 age- and sex-matched normal subjects. Platelet markers (plasma beta-thromboglobulin, soluble glycoprotein V [both ELISA]), coagulation markers (fibrin D-dimer [ELISA] and fibrinogen [Clauss]), and platelet aggregation in response to standard platelet agonists were studied. RESULTS: beta-thromboglobulin (P=0.01), soluble glycoprotein V (P<0.001) and fibrin D-dimer (P=0.002) were higher in untreated AF patients compared to healthy controls. AF patients on warfarin had lower fibrin D-dimer (P<0.001) when compared to AF patients on no therapy. Plasma fibrinogen and platelet aggregation was no different between patients with AF and healthy controls. Aspirin use was associated with reduced platelet aggregation response to epinephrine (P=0.01), whilst patients established on warfarin had significantly lower plasma fibrin D-dimer levels. CONCLUSION: AF patients exhibit changes in plasma markers of platelet function but no significant abnormalities of platelet aggregation. However, treatment with warfarin or aspirin failed to demonstrate any significant benefit on platelet activation, although warfarin use was associated with reduced thrombogenesis (fibrin D-dimer). We suggest that platelet activation may not play an important role in the pathogenesis of thromboembolism in AF.
No takes yet. Share an insight, caveat, or question.
S Kamath (2002) conducted a cross-sectional in Atrial fibrillation (n=288). Antithrombotic therapy (aspirin or warfarin) vs. No antithrombotic therapy and healthy controls was evaluated on Platelet markers (plasma beta-thromboglobulin, soluble glycoprotein V), coagulation markers (fibrin D-dimer and fibrinogen), and platelet aggregation. Untreated atrial fibrillation patients had higher platelet activation markers than healthy controls, and treatment with warfarin or aspirin failed to significantly reduce platelet activation.
Synapse has enriched 10 related papers. Consider them for comparative context: